At the time of writing, Takeda Pharmaceutical Co ADR [TAK] stock is trading at $14.86, up 1.16%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TAK shares have gain 1.85% over the last week, with a monthly amount glided 4.94%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 26, February 2024, Takeda Accelerates Access to its Dengue Vaccine Through ‘Make in India’ Manufacturing Partnership with Biological E. In a post published today on Yahoo Finance, New strategic partnership will scale-up manufacturing capacity to support global supply of dengue vaccine and expands Takeda’s footprint in vaccine manufacturing.
From an analyst’s perspective:
Takeda Pharmaceutical Co ADR [NYSE: TAK] stock has seen the most recent analyst activity on March 16, 2023, when BofA Securities upgraded its rating to a Buy but kept the price target unchanged to $20 for it. Previously, Cowen upgraded its rating to Outperform on July 19, 2022, and elevated its price target to $24. On October 07, 2021, downgrade downgraded it’s rating to Equal-Weight. JP Morgan downgraded its rating to a Neutral. Cowen initiated its recommendation with a Market Perform and recommended $19.50 as its price target on November 01, 2019. Daiwa Securities downgraded its rating to Neutral for this stock on August 15, 2019.
For the past year, the stock price of Takeda Pharmaceutical Co ADR fluctuated between $13.19 and $17.15. Takeda Pharmaceutical Co ADR [NYSE: TAK] shares were valued at $14.86 at the most recent close of the market.
Analyzing the TAK fundamentals
According to Takeda Pharmaceutical Co ADR [NYSE:TAK], the company’s sales were 29.65B for trailing twelve months, which represents an -3.11% plunge. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at 0.08%, Pretax Profit Margin comes in at 0.04%, and Net Profit Margin reading is 0.04%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is 0.03 and Total Capital is 0.03. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.69.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.79 points at the first support level, and at 14.72 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.90, and for the 2nd resistance point, it is at 14.94.
Ratios To Look Out For
It is important to note that Takeda Pharmaceutical Co ADR [NYSE:TAK] has a current ratio of 1.06. Further, the Quick Ratio stands at 0.55, while the Cash Ratio is 0.13. Considering the valuation of this stock, the price to sales ratio is 1.57, the price to book ratio is 0.98 and price to earnings (TTM) ratio is 37.16.
Transactions by insiders
Recent insider trading involved TAKEDA PHARMACEUTICAL CO LTD, 10% Owner, that happened on Jan 24 ’24 when 3.7 million shares were sold.
